Non ‐cardiac comorbidities and intensive up‐titration of oral treatment in patients recently hospitalized for heart failure: Insights from the STRONG‐HF trial

ConclusionsIn the STRONG-HF trial, NCCs neither limited the rapid up-titration of HF therapies, nor attenuated the benefit of HIC on the primary endpoint. In the context of a clinical trial, the benefit –risk ratio favours the rapid up-titration of HF therapies even in patients with multiple NCCs.

Source: European Journal of Heart Failure - October 4, 2023 Category: Cardiology Authors: Ovidiu Chioncel, Beth Davison, Marianna Adamo, Laura E. Antohi, Mattia Arrigo, Marianela Barros, Jan Biegus, Kamil ė Čerlinskaitė‐Bajorė, Jelena Celutkiene, Alain Cohen‐Solal, Albertino Damasceno, Rafael Diaz, Christopher Edwards, Ger Tags: Research Article Source Type: research